Abstract
The relationship between tumour volume response and cell kill in B16 melanoma following treatment in vivo with cyclophosphamide (CY) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) was investigated. Tumour volume response, expressed as growth delay, was estimated from measurements of tumour dimensions. Depression of in vitro colony-forming ability of cells from treated tumours was used as the measure of tumour cell kill. The relationship between these parameters was clearly different for the two agents studied. CY produced more growth delay (7.5 days) per decade of tumour cell kill than CCNU (2 to 3.5 days). The possibility that this was due to a technical artefact was rejected in favour of an alternative explanation that different rates of cellular repopulation in tumours treated with CY and CCNU might be responsible. Cellular repopulation was measured directly, by performing cell-survival assays at various times after treatment with doses of CY and CCNU which produced about 3 decades of cell kill. The rate of repopulation by clonogenic cells was much slower after treatment with CY than with CCNU, and this appears to account for the longer duration of the growth delay obtained with CY.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Stephens, T., Peacock, J. Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Br J Cancer 36, 313–321 (1977). https://doi.org/10.1038/bjc.1977.195
Issue Date:
DOI: https://doi.org/10.1038/bjc.1977.195
This article is cited by
-
The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome
Clinical & Experimental Metastasis (2018)
-
Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
Nature Reviews Clinical Oncology (2016)
-
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor
Cancer Chemotherapy and Pharmacology (2013)
-
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors
BMC Cancer (2009)
-
Reversibility of apoptosis in cancer cells
British Journal of Cancer (2009)